Bluebird Bio reports Q4 EPS ($2.72), consensus ($2.86)

Reports Q4 revenue $19.2M, consensus $8.12M. Cash, cash equivalents and marketable securities as of December 31, 2018 and December 31, 2017 were $1.9 billion and $1.6 billion, respectively. The increase in cash, cash equivalents and marketable securities is primarily related to the completion of a public offering of common stock in July 2018, which raised net proceeds of approximately $600.6 million, the receipt of a $100.0 million investment from Regeneron Pharmaceuticals, Inc. in August 2018, and the completion of a public offering of common stock in January 2018, which raised net proceeds of approximately of $48.7 million.
https://thefly.com/landingPageNews.php?id=2868203